FDA advisory panel votes 10–3 IGNYTE RP1 melanoma efficacy is clinically meaningful, supporting Replimune BLA resubmission
https://finviz.com/stock?t=REPL&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.